ZEUS System (Zio Watch) vs iCAC Device

Tool A offers a more holistic and integrated user experience by providing a patient-facing wearable and app for data collection and symptom logging, alongside a provider portal and mobile app for management. This end-to-end system, including patient engagement tools, addresses a broader spectrum of users and interactions compared to Tool B's focus on integrating into existing radiology workflows.

While both tools offer significant clinical value, Tool A's ability to provide long-term continuous monitoring for up to 14 days and deliver clinically actionable reports with 99% physician agreement for detecting active arrhythmias like AFib offers a more immediate and direct impact on patient management and intervention. Tool B provides valuable risk stratification from opportunistic findings, but Tool A's direct detection of active conditions and high agreement rate gives it a slight edge in immediate clinical actionability.

While both tools require contacting the vendor for specific pricing, Tool B has a clear advantage in demonstrating value through its recently established CMS reimbursement pathway for algorithmic analysis of coronary artery calcium. This provides a clearer framework for financial viability and broader adoption in clinical practice, and its ability to leverage existing scans for early detection can lead to reduced long-term cardiovascular costs.

While Tool A explicitly states HIPAA compliance and BAA in its facts, Tool B demonstrates a more robust enterprise readiness through its explicit mention of integration with PACS, DICOM routers, and EHRs via its Carebricks platform. Furthermore, web search confirms Bunkerhill Health's Trust Center details HIPAA compliance, SOC 2, and ISO 27001:2022 certifications, along with documented business continuity plans, indicating a comprehensive approach to enterprise-level deployment and security.

While Tool A's long-term continuous wearable monitoring is innovative, Tool B's approach of opportunistically extracting critical cardiovascular risk information from *already existing* routine CT scans represents a highly innovative and scalable method to improve early disease detection without additional procedures or radiation exposure. Furthermore, Bunkerhill Health's broader vision with the Carebricks platform, leveraging generative AI for clinical reasoning and automating next steps across various opportunistic findings, demonstrates a more expansive and forward-thinking innovation strategy.

Tool A explicitly provides patient-facing educational content through its MyZio app and comprehensive provider resources via the ZioSuite portal and mobile app. Additionally, web searches confirm dedicated customer care contact information and readily available user manuals and clinical reference manuals, indicating a structured approach to user support and documentation. Tool B's documentation focuses more on technical compliance and platform capabilities rather than direct user support.